US 11,684,627 B2
Wound care formulations with clinically effective active ingredient content
Aisha Chaudhry, Bensalem, PA (US)
Filed by Aisha Chaudhry, Bensalem, PA (US)
Filed on Mar. 17, 2021, as Appl. No. 17/204,265.
Application 17/204,265 is a continuation of application No. 16/915,837, filed on Jun. 29, 2020, abandoned.
Application 16/915,837 is a continuation of application No. 16/458,796, filed on Jul. 1, 2019, granted, now 10,695,356, issued on Jun. 30, 2020.
Application 16/458,796 is a continuation of application No. 15/905,632, filed on Feb. 26, 2018, granted, now 10,335,421, issued on Jul. 2, 2019.
Prior Publication US 2021/0205335 A1, Jul. 8, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/635 (2006.01); A61K 9/00 (2006.01); A61K 36/61 (2006.01); A61K 31/125 (2006.01); A61K 31/045 (2006.01); A61K 38/18 (2006.01); A61K 9/06 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/635 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/045 (2013.01); A61K 31/125 (2013.01); A61K 36/61 (2013.01); A61K 38/1808 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01)] 3 Claims
 
1. A topical formulation, comprising:
(a) at least about 1% silver sulfadiazine;
(b) at least about 0.001% urogastrone; and
(c) an ingredient selected from the group consisting of:
(1) camphor;
(2) menthol; and
(3) eucalyptus;
wherein said ingredient selected from the group in (c) is in a concentration sufficient to provide a clinically effective increase in rate of wound healing when the topical formulation is applied to a wound.